Entries by Karen Hynes

Beta Bionics and ConvaTec announce partnership to bring unomedical infusion set portfolio to the iLet™ Bionic Pancreas System

ConvaTec is a leading global manufacturer of widely popular infusion sets offering a variety of patient choice Beta Bionics is developer of the iLet Bionic Pancreas System and is committed to device interoperability and patient choice ConvaTec will manufacture infusions sets for delivery of both insulin and glucagon via the iLet Bionic Pancreas System Boston, […]

Beta Bionics announces closing of a $63 million Series B2 financing, bringing the total Series B and B2 financings to $126 million

The round was co-led by new investors Perceptive Advisors and Soleus Capital New investor Farallon Capital also participated in the round, as did previous Series B investors RTW Investments, ArrowMark Partners and funds managed by Eventide Asset Management Funds will support final product development, regulatory submission and commercial launch of the iLet TM Bionic Pancreas […]

Beta Bionics and Zealand Pharma announce superior glycemic control in phase 2 home-use clinical trial testing the iLet™ Bionic Pancreas using dasiglucagon

First home-use trial of the iLet Bionic Pancreas System using pre-filled cartridges of dasiglucagon compatible with iLet has been successfully completed The preliminary study results reveal superior blood glucose control during the study period that used the bihormonal configuration of the iLet with dasiglucagon compared to the period that used the insulin-only configuration iLet therapy […]

Beta Bionics and Zealand Pharma initiate home-use trial of the iLet™ bionic pancreas with dasiglucagon for autonomous bihormonal treatment of Type 1 diabetes

First home-use trial of the bihormonal iLet Bionic Pancreas System with dasiglucagon in a pre-filled, commercial-ready, pump cartridge has been initiated by a clinical team at Massachusetts General Hospital The iLet Bionic Pancreas System is a pocket-sized, wearable medical device that autonomously controls blood-sugar levels in people with diabetes Dasiglucagon is a potential first-in-class stable […]

Beta Bionics Announces Final Closing of Its $63 Million Series B Financing

New investors include ArrowMark, LifeSci Venture Partners, and strategic partner, Dexcom RTW made an additional Series B investment Strategic partner, Zealand Pharma completed $5 million Series B investment BOSTON, Jan. 08, 2019 (GLOBE NEWSWIRE) — Beta Bionics, Inc. – a medical technology company leveraging lifelong, machine-learning, artificial intelligence to develop and commercialize the world’s first autonomous […]

Beta Bionics awarded up to $2 million NIH small business innovation research (SBIR) grant

Award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Grant provides up to $2 million in funding over the next 24 months under the Fast-Track mechanism (pending demonstration of successful achievement of Phase I milestones) Research activities directed toward the Beta Bionics insulin-only and bihormonal bionic pancreas technology. Boston, MA – […]

Beta Bionics secures an initial $50 million Series B round

The round was led by Eventide Asset Management Other institutional investors in Series B include RTW Investments Corporate strategic partner and Series A investor, Novo Nordisk, has also participated in Series B Corporate strategic partner, Zealand Pharm, previously committed $5m to Series B in December 2017 Boston, MA – September 17, 2018 – Beta Bionics, Inc. […]

Beta Bionics Announces Start of Home-Use Clinical Trials with the iLet™ Bionic Pancreas System and Receives IDE Approval from the FDA to Expand its Clinical Trials to Include the Senseonics Eversense CGM Integrated into the iLet

The Beta Bionics iLet Bionic Pancreas System is now approved for clinical trials in adults with type 1 diabetes (T1D) using two highly accurate continuous glucose monitoring (CGM) systems: the Dexcom CGM and the Senseonics Eversense CGM iLet compatibility with both CGM systems demonstrates unique commitment by Beta Bionics to patient choice, interoperability, and the […]

Beta Bionics Receives IDE Approval from the FDA to Begin a Home-Use Clinical Trial Testing the New iLet™ Bionic Pancreas System

First trial to test Fiasp® – Novo Nordisk’s latest formulation of fast-acting insulin aspart – using autonomous insulin delivery The bionic pancreas will also be tested with the conventional formulations of insulin aspart and insulin lispro in both adults and children with type 1 diabetes who use either an insulin pump or multiple daily injection […]